We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Protea, MSK, Dana-Farber Enter Collaborative Research Agreement
News

Protea, MSK, Dana-Farber Enter Collaborative Research Agreement

Protea, MSK, Dana-Farber Enter Collaborative Research Agreement
News

Protea, MSK, Dana-Farber Enter Collaborative Research Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Protea, MSK, Dana-Farber Enter Collaborative Research Agreement "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Protea Biosciences Group, Inc. announced it has begun a collaborative research initiative with the Memorial Sloan-Kettering Cancer Center (MSK) and the Dana-Farber Cancer Institute (Dana-Farber) that uses Protea’s next generation LAESI direct molecular imaging technology to analyze cancer cells. The initial focus is early stage lung adenocarcinoma. 

The studies will utilize LAESI technology to generate molecular data profiles of cancer cells in tissue and biofluids to improve the understanding of a cancer’s origin. Protea’s proprietary LAESI technology generates very large molecular data profiles of cancer cells in their native state, without the need for time-consuming sample preparation. 

The principal investigators are Robert J. Downey, M.D. and Andre Moreira, M.D. at MSK and Franziska Michor, Ph.D. at Dana-Farber. 

“We are pleased to have this opportunity to apply our LAESI technology to provide improved molecular profiling of cancer cells and tissue samples,” commented Steve Turner, Protea’s CEO. He added, “In the future we anticipate applying our direct molecular profiling technology to other tissue sample types, including 3 dimensional cell cultures and synthetic biology tissues, to provide comprehensive molecular profiling of tumors rapidly and directly. 

Advertisement